Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight weeks~* HbA1c greater than or equal to 7.0% and less than 10.0%~* BMI (Body Mass Index) less than 35 kg/m2~Exclusion Criteria:~* Treatment with insulin within the last 12 weeks~* Treatment with any drug that could interfere with the glucose level~* Any serious medical condition~* Females who are pregnant, have intention of becoming pregnant or are breastfeeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): Liraglutide 0.9 mg + glibenclamide placebo
- Glibenclamide (Type: ACTIVE_COMPARATOR): Glibenclamide 1.25-2.5 mg + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).